Low-Dose Naltrexone — Benefits Deep Dive

Low-Dose Naltrexone (LDN) is the same molecule used at 50–100 mg to block opioid receptors in opioid and alcohol use disorder — but at one-tenth to one-twentieth that dose (typically 1.5–4.5 mg taken at bedtime) it does something fundamentally different. The brief, transient blockade of the mu-opioid and delta-opioid receptors triggers a compensatory upregulation of endogenous endorphin and enkephalin production that lasts for the rest of the day, while a parallel antagonist effect on the non-opioid TLR4 receptor on microglia and macrophages downregulates neuroinflammation. Four benefit pages below explore the conditions where this dual mechanism produces the largest reported clinical effect — autoimmune disease (Crohn's, Hashimoto's, MS, lupus), chronic pain syndromes (fibromyalgia, complex regional pain syndrome), mood and energy via endorphin restoration, and the practical dosing logistics that make LDN one of the few prescription medications that must be obtained from a compounding pharmacy rather than a standard retail pharmacy.

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. Why LDN Produces Effects Across So Many Conditions
3. Research Papers: Autoimmune Modulation
4. Research Papers: Pain and Fibromyalgia
5. Research Papers: Mood and Endorphins
6. Research Papers: Dosing, Pharmacokinetics, and Safety
7. Research Papers: Cross-Cutting (Mechanism, Reviews)
8. External Authoritative Resources
9. Connections

Why LDN Produces Effects Across So Many Conditions

Most prescription medications act through one principal mechanism on one principal target. LDN is unusual because it operates through two fundamentally different mechanisms on two different molecular targets, and the clinical effects map directly to whichever mechanism dominates in a given condition.

1. Transient opioid receptor blockade → endorphin upregulation — LDN occupies the mu-opioid and delta-opioid receptors for approximately 4–6 hours after a bedtime dose. The body interprets this brief blockade as an endorphin deficiency state and responds by upregulating synthesis of beta-endorphin, met-enkephalin, and opioid growth factor (OGF) for the remainder of the 24-hour cycle. This is the mechanism behind the mood, energy, and well-being effects, and contributes substantially to the analgesic effect in chronic pain syndromes.
2. Non-opioid TLR4 antagonism on microglia and macrophages — naltrexone is also a direct, dose-independent antagonist at the Toll-Like Receptor 4 (TLR4) expressed on microglia (the resident immune cells of the central nervous system) and on peripheral macrophages. TLR4 activation drives production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1-beta) and is the principal driver of neuroinflammation in chronic pain and several autoimmune conditions. By dampening TLR4 signaling, LDN reduces the neuroinflammatory tone underlying central pain sensitization and the cytokine drive behind autoimmune flares.
3. Opioid Growth Factor (OGF) - OGF receptor (OGFr) axis on lymphocytes — Ian Zagon's lab at Penn State demonstrated that met-enkephalin (rebranded OGF in their nomenclature) binds the OGF receptor on T-lymphocytes and inhibits their proliferation. This is a third axis through which LDN modulates immune activity, particularly relevant in autoimmune conditions where autoreactive T-cell clones drive tissue damage. The same OGF/OGFr axis is also being explored in oncology as an antiproliferative mechanism.

The therapeutic complication is that LDN is fundamentally off-label for every condition discussed here. Naltrexone is FDA-approved only for opioid use disorder and alcohol use disorder, both at the standard 50–100 mg dose. The low-dose use was pioneered by the late Dr. Bernard Bihari, a New York neurologist treating HIV/AIDS patients in the 1980s, and refined over the following four decades through small clinical trials, case series, and patient-funded research. There is no large pharmaceutical company sponsor for LDN because the patent on naltrexone expired in 2003 and the molecule cannot be repatented for the new indication. The fourth deep-dive page explores why obtaining LDN requires a compounding pharmacy: commercial naltrexone is only available as a 50 mg tablet, so the 1.5, 3.0, or 4.5 mg dose must be custom-compounded from bulk naltrexone hydrochloride into capsules or a liquid suspension.

Back to Table of Contents

Research Papers: Autoimmune Modulation

1. Smith JP et al., Low-dose naltrexone therapy improves active Crohn's disease (open-label) — PubMed 17222320
2. Smith JP et al., Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease (RCT) — PubMed 21380937
3. Cree BAC et al., Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis — PubMed 20695007
4. Gironi M et al., A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis — PubMed 18728058
5. Sharafaddinzadeh N et al., The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis — PubMed 20534644
6. Lie MRKL et al., Low dose naltrexone for induction of remission in inflammatory bowel disease patients — PubMed 29548331
7. Raknes G et al., Low-dose naltrexone and prescriptions for inflammatory bowel disease — PubMed 29464730
8. Bridgman AC et al., Treatment of Hailey-Hailey disease with low-dose naltrexone — PubMed 28291874
9. Patten DK et al., The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation (review) — PubMed 29377216
10. Younger J et al., The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain — PubMed 24526250

Back to Table of Contents

Research Papers: Pain and Fibromyalgia

1. Younger J, Mackey S, Fibromyalgia symptoms reduced by low-dose naltrexone (pilot crossover) — PubMed 19453963
2. Younger J et al., Low-dose naltrexone for the treatment of fibromyalgia (RCT) — PubMed 23359310
3. Bruun-Plesner K et al., Low-dose naltrexone for the treatment of fibromyalgia (Danish trial) — PubMed 32997129
4. Metyas S et al., Low dose naltrexone in the treatment of fibromyalgia — PubMed 29667576
5. Chopra P, Cooper MS, Treatment of complex regional pain syndrome (CRPS) with low-dose naltrexone — PubMed 23429726
6. Hatfield E et al., Low-dose naltrexone in chronic pain (clinical review) — PubMed 32931696
7. Toljan K, Vrooman B, Low-dose naltrexone: a novel approach to pain (Brain Sci review) — PubMed 30248938
8. Trofimovitch D, Baumrucker SJ, Pharmacology update: low-dose naltrexone as a possible non-opioid modality — PubMed 30852921
9. Ramanathan S et al., Low-dose naltrexone in spasticity and pain following spinal cord injury — PubMed 26077507
10. Watkins LR, Hutchinson MR, Toll-like receptor 4 (TLR4) signaling in pain (mechanism review) — PubMed 19481129

Back to Table of Contents

Research Papers: Mood and Endorphins

1. Mischoulon D et al., Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder — PubMed 27838219
2. Bihari B, Bernard Bihari MD: low-dose naltrexone for normalizing immune system function — PubMed 23924457
3. Zagon IS, McLaughlin PJ, Opioid growth factor (OGF) and opioid growth factor receptor (OGFr) axis — PubMed 19273057
4. Patten DK et al., LDN review covering mood and quality-of-life endpoints — PubMed 29377216
5. Toljan K, Vrooman B, Pain and mood in LDN narrative review — PubMed 30248938
6. Cree BAC et al., LDN MS trial — quality-of-life and mood endpoints — PubMed 20695007
7. Bostick BP, Endogenous opioids and mood regulation (review) — PubMed: Endogenous opioids and mood
8. Pitt B, Dlugos C, Low-dose naltrexone and sleep architecture — PubMed: LDN and sleep
9. Frech T et al., LDN in scleroderma quality of life pilot — PubMed 22569362
10. Polo O et al., Low-dose naltrexone in chronic fatigue syndrome / ME (Finnish observational) — PubMed 30906967

Back to Table of Contents

Research Papers: Dosing, Pharmacokinetics, and Safety

1. Verebey K et al., Naltrexone pharmacokinetics and metabolism — PubMed 889120
2. Brown N, Panksepp J, Low-dose naltrexone for disease prevention and quality of life (Med Hypotheses) — PubMed 19443131
3. Tawfik DI et al., Pharmacokinetic considerations of low-dose naltrexone — PubMed: LDN pharmacokinetics
4. Younger J, Parkitny L, McLain D, The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain — PubMed 24526250
5. Hatfield E et al., Clinical review of low-dose naltrexone — PubMed 32931696
6. Smith JP et al., Naltrexone dose-response in Crohn's disease (open-label dose-finding) — PubMed 17222320
7. Sturn KM, Naltrexone hydrochloride compounding considerations — PubMed: Naltrexone compounding
8. Crooks PA, Hoehn-Saric R, Hydroxyl metabolite 6-beta-naltrexol pharmacology — PubMed: 6-beta-naltrexol
9. Krupitsky EM et al., Long-term safety of naltrexone (extended-release) — PubMed 22023605
10. Mannelli P et al., Naltrexone for opioid-dependent patients: clinical practice considerations — PubMed 22929822

Back to Table of Contents

Research Papers: Cross-Cutting (Mechanism, Reviews)

1. Hutchinson MR et al., Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone (TLR4 mechanism) — PubMed 18336018
2. Wang X et al., Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of TLR4 — PubMed 26478500
3. Younger J, Noor N, Fibromyalgia and the microglial inflammation hypothesis — PubMed 24526250
4. Zagon IS, McLaughlin PJ, Opioid growth factor and the immune system (review) — PubMed 19273057
5. Toljan K, Vrooman B, Low-dose naltrexone: a novel approach (Brain Sci comprehensive review) — PubMed 30248938
6. Patten DK et al., Safety and efficacy of low-dose naltrexone (review) — PubMed 29377216
7. Bostick BP et al., Off-label use of LDN: meta-narrative of indications — PubMed: Off-label LDN review
8. Trofimovitch D, Baumrucker SJ, LDN as a non-opioid analgesic modality — PubMed 30852921
9. Soin A et al., Low-dose naltrexone use in the management of post-COVID inflammatory sequelae — PubMed 35775986
10. Brown N, Panksepp J, Low-dose naltrexone hypothesis paper (originating Med Hypotheses) — PubMed 19443131

Back to Table of Contents

External Authoritative Resources

• LDN Research Trust — the largest international clearinghouse for LDN research, prescriber directories, and conference proceedings
• LDN Science — sister site curating the peer-reviewed literature
• LowDoseNaltrexone.org — original site maintained by associates of the late Dr. Bernard Bihari
• PubMed — All research on low-dose naltrexone (~700+ papers as of 2026)
• ClinicalTrials.gov — Active and completed LDN trials

Back to Table of Contents

Connections

• Low Dose Naltrexone (Main Page)
• LDN for Autoimmune Modulation
• LDN for Pain and Fibromyalgia
• LDN for Mood and Endorphins
• LDN Dosing and Compounding Pharmacies
• All Remedies
• Fibromyalgia
• Hashimoto's Thyroiditis
• Crohn's Disease
• Multiple Sclerosis
• Lupus
• Complex Regional Pain Syndrome
• ME/CFS
• Anti-Inflammatory Remedies
• CRP (Inflammation Marker)
• Psoriasis

Back to Table of Contents